Placeholder

Companion Diagnostics: Partnering for Success

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

Product Description

As the development of personalized medicine gains momentum, device and pharmaceutical companies are collaborating in their development efforts. They are creating partnerships for the development of diagnostics to accompany clinical trials.
In fact, there has been an acceleration of companion diagnostics partnerships, according to a report published last December by PwC. This will continue as long as innovation and growth continues in key areas, such as molecular…

Sidebar:
The In Vitro Diagnostics Market

Experts
Robert Copeland, Ph.D.
  Chief Scientific Officer, Epizyme, which is creating personalized therapeutics for ­patients with genetically defined cancers. For more information, visit epizyme.com.
Trevor Hawkins. Senior VP, Strategy and Innovation, Siemens Healthcare Diagnostics, which provides in vitro
diagnostics to healthcare professionals in hospital, reference, and physician office laboratories. For more information, visit siemens.com/healthcare.
Eric Hedrick, M.D. Chief ­Medical Officer, Epizyme, which is creating personalized therapeutics for patients with genetically defined cancers. For more information, visit epizyme.com.
Walter Koch, Ph.D. VP and Head, Global Research, Roche Molecular Diagnostics, which ­offers a broad range of ­diagnostic and blood-screening assays based on the company’s PCR technologies. For more information, visit molecular.roche.com.
Theresa LaVallEe, Ph.D.  Senior ­Director of Translational ­Sciences Oncology, ­MedImmune, the global ­biologics arm of AstraZeneca PLC.  For more information, visit medimmune.com.

FEEDBACK